Aethlon Medical assumed with a Neutral at H.C. Wainwright

H.C. Wainwright assumed coverage of Aethlon Medical (AEMD) with a Neutral rating and $1.50 price target The company is focused on developing and commercializing Hemopurifier, a medical device designed to deplete cancer-promoting exosomes or extracellular vesicles, the analyst tells investors in a research note. The firm is encouraged by Hemopurifier’s market potential, but sees no major catalysts in the next 12 months.